Susquehanna International Group
ALDX icon

Susquehanna International Group’s Aldeyra Therapeutics ALDX Stock Holding History

Susquehanna International Group’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$471K Buy
278,442
+215,535
+343% +$944K ﹤0.01% 9835
2025
Q4 		$326K Sell
62,907
-95,476
-60% -$490K ﹤0.01% 9762
2025
Q3 		$827K Sell
158,383
-73,383
-32% -$383K ﹤0.01% 7802
2025
Q2 		$888K Buy
231,766
+166,458
+255% +$430K ﹤0.01% 7735
2025
Q1 		$376K Sell
65,308
-26,438
-29% -$156K ﹤0.01% 9560
2024
Q4 		$458K Buy
91,746
+64,314
+234% +$330K ﹤0.01% 8896
2024
Q3 		$148K Buy
27,432
+10,669
+64% +$50.8K ﹤0.01% 10755
2024
Q2 		$55.5K Sell
16,763
-23,154
-58% -$90.7K ﹤0.01% 11365
2024
Q1 		$131K Sell
39,917
-162,279
-80% -$534K ﹤0.01% 11023
2023
Q4 		$710K Sell
202,196
-139,214
-41% -$430K ﹤0.01% 7815
2023
Q3 		$2.28M Buy
341,410
+99,743
+41% +$740K ﹤0.01% 4874
2023
Q2 		$2.03M Sell
241,667
-856,501
-78% -$8.44M ﹤0.01% 5134
2023
Q1 		$10.9M Buy
1,098,168
+852,019
+346% +$6.02M ﹤0.01% 2327
2022
Q4 		$1.71M Buy
246,149
+113,455
+86% +$649K ﹤0.01% 5009
2022
Q3 		$709K Buy
132,694
+60,452
+84% +$363K ﹤0.01% 7527
2022
Q2 		$288K Buy
72,242
+30,528
+73% +$105K ﹤0.01% 9667
2022
Q1 		$185K Sell
41,714
-89,774
-68% -$358K ﹤0.01% 11322
2021
Q4 		$526K Sell
131,488
-39,626
-23% -$302K ﹤0.01% 9047
2021
Q3 		$1.5M Buy
171,114
+54,655
+47% +$502K ﹤0.01% 6473
2021
Q2 		$1.32M Sell
116,459
-154,268
-57% -$1.85M ﹤0.01% 6994
2021
Q1 		$3.22M Buy
270,727
+194,854
+257% +$2.24M ﹤0.01% 4795
2020
Q4 		$520K Buy
75,873
+62,247
+457% +$437K ﹤0.01% 8199
2020
Q3 		$101K Sell
13,626
-6,646
-33% -$42.9K ﹤0.01% 9911
2020
Q2 		$85K Sell
20,272
-3,221
-14% -$11.8K ﹤0.01% 9566
2020
Q1 		$58K Buy
23,493
+6,254
+36% +$28.1K ﹤0.01% 9604
2019
Q4 		$100K Sell
17,239
-11,790
-41% -$68.1K ﹤0.01% 9139
2019
Q3 		$153K Sell
29,029
-18,130
-38% -$97.6K ﹤0.01% 9308
2019
Q2 		$283K Buy
47,159
+30,893
+190% +$232K ﹤0.01% 8428
2019
Q1 		$147K Sell
16,266
-9,170
-36% -$77.9K ﹤0.01% 8063
2018
Q4 		$211K Buy
25,436
+10,397
+69% +$107K ﹤0.01% 7631
2018
Q3 		$208K Buy
+15,039
New +$122K ﹤0.01% 8145
2018
Q2 		– Sell
-44,084
Closed -$331K – 9537
2018
Q1 		$331K Buy
+44,084
New +$335K ﹤0.01% 7454

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group's ALDX Position: Q1 2026 in Review

Susquehanna International Group increased its Aldeyra Therapeutics (ALDX) stake by 343% in Q1 2026, buying an estimated $944K and bringing the position to 278,442 shares worth $471K. The position accounts for ﹤0.01% of the portfolio, ranked #9835.

Susquehanna International Group first reported a position in ALDX in Q1 2018 and has held it in 32 quarters since. The position peaked at $10.9M in Q1 2023. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Susquehanna International Group held 278,442 shares of Aldeyra Therapeutics worth $471K as of Q1 2026.
  • Susquehanna International Group bought 215,535 Aldeyra Therapeutics shares in Q1 2026, an estimated $944K.
  • Aldeyra Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9835 holding.
  • Susquehanna International Group first reported a position in Aldeyra Therapeutics in Q1 2018 and has held it in 32 quarters since.
  • Susquehanna International Group's Aldeyra Therapeutics position peaked at $10.9M in Q1 2023.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.